Morgan BP - Search Results

1

Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex.

Heurich M, Preston RJ, O'Donnell VB, Morgan BP, Collins PW. Heurich M, et al. Among authors: morgan bp. Thromb Res. 2016 Sep;145:84-92. doi: 10.1016/j.thromres.2016.07.017. Epub 2016 Aug 2. Thromb Res. 2016. PMID: 27513882

2

Terminal complement complexes and C1/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions.

Oleesky DA, Daniels RH, Williams BD, Amos N, Morgan BP. Oleesky DA, et al. Among authors: morgan bp. Clin Exp Immunol. 1991 May;84(2):250-5. Clin Exp Immunol. 1991. PMID: 2025952 Free PMC article.

3

Immunocytochemical localization of the terminal complement complex in multiple sclerosis.

Compston DA, Morgan BP, Campbell AK, Wilkins P, Cole G, Thomas ND, Jasani B. Compston DA, et al. Among authors: morgan bp. Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):307-16. doi: 10.1111/j.1365-2990.1989.tb01231.x. Neuropathol Appl Neurobiol. 1989. PMID: 2779734

4

Enhanced complement susceptibility of avidin-biotin-treated human erythrocytes is a consequence of neutralization of the complement regulators CD59 and decay accelerating factor.

Zaltzman AB, Van den Berg CW, Muzykantov VR, Morgan BP. Zaltzman AB, et al. Among authors: morgan bp. Biochem J. 1995 May 1;307 ( Pt 3)(Pt 3):651-6. doi: 10.1042/bj3070651. Biochem J. 1995. PMID: 7537958 Free PMC article.

5

Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP).

Pérez De La Lastra JM, Van Den Berg CW, Bullido R, Almazán F, Domínguez J, Llanes D, Morgan BP. Pérez De La Lastra JM, et al. Among authors: morgan bp. Immunology. 1999 Apr;96(4):663-70. doi: 10.1046/j.1365-2567.1999.00732.x. Immunology. 1999. PMID: 10233756 Free PMC article.

6

Differential expression of individual complement regulators in the brain and choroid plexus.

Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Singhrao SK, et al. Among authors: morgan bp. Lab Invest. 1999 Oct;79(10):1247-59. Lab Invest. 1999. PMID: 10532588 Clinical Trial.

7

The complement system: an overview.

Morgan BP. Morgan BP. Methods Mol Biol. 2000;150:1-13. doi: 10.1385/1-59259-056-X:1. Methods Mol Biol. 2000. PMID: 10857099 Review. No abstract available.

8

Measurement of complement hemolytic activity, generation of complement-depleted sera, and production of hemolytic intermediates.

Morgan BP. Morgan BP. Methods Mol Biol. 2000;150:61-71. doi: 10.1385/1-59259-056-X:61. Methods Mol Biol. 2000. PMID: 10857102 No abstract available.

9

Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Harris CL, Spiller OB, Morgan BP. Harris CL, et al. Among authors: morgan bp. Immunology. 2000 Aug;100(4):462-70. doi: 10.1046/j.1365-2567.2000.00066.x. Immunology. 2000. PMID: 10929073 Free PMC article.

10

Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis.

Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Singhrao SK, et al. Among authors: morgan bp. Am J Pathol. 2000 Sep;157(3):905-18. doi: 10.1016/S0002-9440(10)64604-4. Am J Pathol. 2000. PMID: 10980130 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

535 results

Search Page

Filters